Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedLoading investors…
Activity from announced rounds
Develops neuro-metabolic therapeutics for schizophrenia and ALS
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies